How It Works
GLP-1 Observer ranks clinical trials to surface the most commercially relevant programs first. Here's how to get the most out of the dashboard.
How Trials Are Ranked
Each trial receives a score based on multiple factors that indicate commercial relevance and near-term importance:
Phase Weight
Phase 3 trials score highest, followed by Phase 2. Later-stage trials are closer to market and more actionable.
Sponsor Profile
Major pharmaceutical sponsors (Novo Nordisk, Eli Lilly, etc.) receive a boost, signaling higher likelihood of commercialization.
Completion Proximity
Trials nearing their primary completion date get priority. Results within 90-180 days are especially weighted.
Scale Indicators
Large enrollment and multi-site trials suggest well-funded, pivotal programs with higher commercial stakes.
Novel Mechanisms
Tri-agonists, amylin combinations, and other emerging mechanisms get a novelty boost in relevant views.
Recent Updates
Trials updated within the last 30 days score higher, indicating active development.
Dashboard Views
Competitive Pipeline
A swimlane chart showing drug programs from company pipeline pages, color-coded by mechanism and mapped to their clinical trial phases. Trial badges link directly to ClinicalTrials.gov entries. For a detailed guide to reading the chart, look for the ⓘ icon in the Pipeline tab header.
Drugs
Select any drug to see its full trial history on an interactive timeline. Bars are color-coded by phase, and endpoint markers show which trials met their primary endpoints, missed, or posted results. Filter by indication or sponsor type. Click any trial bar to drill down to detailed trial information.
Commercial Leaders
Phase 3 programs from major sponsors, ordered by commercial momentum. Best for tracking the frontrunners likely to reach market first.
Emerging Mechanisms
Novel drug mechanisms and early-stage innovation from smaller sponsors. Highlights tri-agonists, oral formulations, and differentiated approaches.
Upcoming Readouts
Trials with near-term primary completion dates. Useful for anticipating catalyst events and data announcements.
Weekly Updates
A curated digest of the week's highlights, significant trial date changes, industry news, and newly registered trials. Updated weekly.
Watched
Your personal watchlist. Watch any trial from any view using the bell icon, and this tab collects date changes, status moves, results, enrollment changes, and more for just those trials. Color-coded badges show delays (orange) and advances (green).
Using the Dashboard
Opening Trial Details
Click any row to open the detail drawer on the right. The drawer shows trial summary, mechanism details, timeline history, enrollment data, and results if available.
Filtering & Sorting
Use the filter inputs to narrow by drug name, company, or phase. Sort by enrollment, completion date, or other columns using the dropdown.
Drawer Tabs
- Overview: Trial summary, drugs, differentiation, and links
- Timeline: Visual timeline of milestones and date changes
- Results: Posted results, endpoints, and safety data (when available)
- Enrollment: World map of trial sites, country-by-country breakdown, and enrollment velocity chart (when data is available)
Watching Trials
Click the bell icon on any trial row to add it to your watchlist. Watched trials appear in the Watched tab with a summary of recent changes. Configure email alerts for your watched trials on the Alerts settings page — choose daily or weekly digests and control which categories of changes you hear about (date changes, results, enrollment, phase changes, press mentions).
Selecting Trials
Use the checkboxes in the left column to select multiple trials. Selected trials can be added to your watchlist in bulk.
Keyboard Shortcuts
Power users can navigate the dashboard entirely with the keyboard:
Data Sources
Trial data is sourced from ClinicalTrials.gov and updated daily. Historical change tracking uses AACT (Aggregate Analysis of ClinicalTrials.gov) for 5+ years of timeline data.
Drug mechanisms, press releases, results, and other data are enriched using AI-powered research and are cited to allow verification. Information on the site undergoes evaluations and expert human validation, but you should always verify critical details against primary sources.
Questions or Feedback?
Have a question that's not answered here, want to suggest a feature, or report a bug? We'd love to hear from you.
Send Feedback →